Results 121 to 130 of about 446,414 (163)

Hyperthermic Intraperitoneal Chemotherapy

2017
Peritoneal metastasis in abdominal malignancies is associated with a dismal prognosis. In the past, it was considered inoperable and the patient was considered a candidate for palliative chemotherapy alone. The outcome of systemic chemotherapy is poor with the average survival being 6–8 months.
Nikhil Gupta, Shivendra Singh
openaire   +1 more source

Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer

Gynecologic Oncology, 2004
To evaluate the clinical effect of intraperitoneal hyperthermic chemotherapy (IPHC) in ovarian cancer patients.We retrospectively reviewed 117 stages Ic-III ovarian cancer patients, who were diagnosed at the Gynecology Department of Kangnam St. Mary's Hospital between January 1994 and January 2000. Of these, 57 patients underwent cytoreductive surgery (
Jin Woo Kim, Hyun Sun Ko, Yong Gyu Park
exaly   +3 more sources

Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer

JAAPA, 2021
ABSTRACT Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used for decades as a treatment for disseminated abdominal malignancies, including pseudomyxoma peritonei and peritoneal mesothelioma. HIPEC had been used to treat recurrent ovarian cancer only when curative options were lacking, but new data indicate that it may be suitable ...
Shilpa, Gajarawala, Jessica, Pelkowski, Rose, Dorian, Amanda, Stanton, Tri, Dinh   +4 more
openaire   +2 more sources

Intraperitoneal hyperthermic chemotherapy in ovarian cancer

International Journal of Gynecological Cancer, 2005
We investigated the effect of intraperitoneal hyperthermic perfusion chemotherapy as consolidation therapy in stage IIIB-IIIC ovarian cancer, following cytoreductive surgery and systemic chemotherapy (cisplatin-cyclophosphamide--six cycles). Disease-free survival, overall survival, and side effects were compared with a control group of patients who ...
J, Gori, R, Castaño, M, Toziano, D, Häbich, J, Staringer, D G B, De Quirós, N, Felci   +6 more
openaire   +2 more sources

Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer

Journal of Obstetrics and Gynaecology Research, 2020
AbstractAimHyperthermic intraperitoneal chemotherapy (HIPEC) is a method of administering anticancer agents directly while heating the abdominal cavity. The aim of this review is to know the current position of HIPEC in ovarian cancer and uterine sarcoma and its future prospects.MethodsThis article reviews the current literature and evidence for the ...
Hideaki, Tsuyoshi, Daisuke, Inoue, Tetsuji, Kurokawa, Yoshio, Yoshida   +3 more
openaire   +2 more sources

Cytoreduction and hyperthermic intraperitoneal chemotherapy: The learning curve reassessed

European Journal of Surgical Oncology (EJSO), 2016
CytoReductive Surgery and Hyperthermic IntraPEritoneal Chemotherapy (CRS-HIPEC) is now the preferred treatment of many peritoneal surface malignancies. In this retrospective study we aimed to analyze how several performance indicators changed during the first 100 CRS-HIPEC procedures in hospitals which recently introduced this treatment, and compare ...
Kuijpers, A. M., Hauptmann, M., Aalbers, A. G., Nienhuijs, S. W., de Hingh, I. H., Wiezer, M. J., van Ramshorst, B., van Ginkel, R. J., Havenga, K., Verwaal, V. J.   +9 more
openaire   +2 more sources

[Hyperthermic intraperitoneal chemotherapy].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2019
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are recognized as the standard of care for selected patients with peritoneal malignancies. A complete macroscopic cytoreduction is the basis for a successful multimodal treatment. The significance of intraperitoneal chemotherapy is still under discussion.
H, Leebmann, P, Piso
openaire   +1 more source

Laparoscopic hyperthermic intraperitoneal chemotherapy for appendiceal tumors

Asian Journal of Endoscopic Surgery, 2020
AbstractIntroductionThe application of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal and appendix cancer at risk of peritoneal seeding is an appealing strategy to prevent peritoneal metastases. Here, we present the technical details and postoperative outcomes of laparoscopic HIPEC performed with prophylactic intent in three patients ...
Antonio Sommariva, Marco Tonello, Ottavia De Simoni, Andrea Barina, Carlo Riccardo Rossi, Pierluigi Pilati   +5 more
openaire   +2 more sources

Selection of Chemotherapy in Hyperthermic Intraperitoneal Chemotherapy

2017
The peritoneum consists of a layer of mesothelial cells covering all abdominal organs and the abdominopelvic wall. Peritoneal metastases are formed after exfoliation of free tumor cells from a primary tumor invading the peritoneum. Consequently, most peritoneal metastases originate from abdominal organs such as the colon, rectum, stomach, or ovaria ...
H. J. Braam, F. J. H. Hoogwater
openaire   +1 more source

Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer

Current Treatment Options in Oncology
In our clinical practice, we have shifted away from the use of adjuvant normothermic intraperitoneal (IP) chemotherapy, particularly following the publication of GOG 252. Our decision is rooted in the accumulating evidence indicating a lack of demonstrable superiority, alongside the recognized toxicities and logistical challenges associated with its ...
Joyce Y, Wang, Maya, Gross, Renata R, Urban, Soledad, Jorge   +3 more
openaire   +2 more sources